[(3-硝基苯甲酰基)氨基]硫脲 | 886-29-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: [(3-硝基苯甲酰基)氨基]硫脲
• 英文名称: 1-(3-Nitro-benzoyl)-thiosemicarbazid
• 英文别名: 2-(3-Nitrobenzoyl)hydrazine-1-carbothioamide；[(3-nitrobenzoyl)amino]thiourea
• CAS: 886-29-3
• 化学式: C₈H₈N₄O₃S
• 分子量: 240.243
• InChiKey: LUOBFXIDRRJNIF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  145
• 氢给体数：
  3
• 氢受体数：
  4

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  [(3-硝基苯甲酰基)氨基]硫脲 在 potassium hydroxide 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 2-((4-amino-5-(3-nitrophenyl)-4H-1,2,4-triazol-3-yl)thio)-N-(benzoxazol-2-yl)acetamide
  参考文献：
  名称：

  Azolylthioacetamides as a potent scaffold for the development of metallo-β-lactamase inhibitors

  摘要：

  In an effort to develop new inhibitors of metallo-beta-lactamases (MbLs), twenty-eight azolylthioacetamides were synthesized and assayed against MbLs. The obtained benzimidazolyl and benzioxazolyl substituted 1-19 specifically inhibited the enzyme ImiS, and 10 was found to be the most potent inhibitor of ImiS with an IC50 value of 15 nM. The nitrobenzimidazolyl substituted 20-28 specifically inhibited NDM-1, with 27 being the most potent inhibitor with an IC50 value of 170 nM. Further studies with 10, 11, and 27 revealed a mixed inhibition mode with competitive and uncompetitive inhibition constants in a similar range as the IC50 values. These inhibitors resulted in a 2-4-fold decrease in imipenem MIC values using E. coli cells producing ImiS or NDM-1. While the source of uncompetitive (possibly allosteric) inhibition remains unclear, docking studies indicate that 10 and 11 may interact orthosterically with Zn2 in the active site of CphA, while 27 could bridge the two Zn(II) ions in the active site of NDM-1 via its nitro group. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.10.038
• 作为产物：
  描述：

  间硝基苯甲酸 在 吡啶 、 氯化亚砜 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 生成 [(3-硝基苯甲酰基)氨基]硫脲
  参考文献：
  名称：

  新型人参二醇三唑衍生物通过线粒体途径诱导HepG-2细胞凋亡。

  摘要：

  在这项研究中，我们将1，2，4-三唑基引入人参二醇（PD）中，以获得18种人参二醇三唑衍生物。通过MTT测定评估了5个癌细胞和1个正常细胞的细胞毒性。结果表明，大多数衍生物均可抑制癌细胞的增殖，化合物A1的抗增殖活性最为显着。对于HepG-2细胞，IC 50值为4.21±0.54μM，几乎是PD活性的15倍。进一步的研究表明，化合物A1可以诱导HepG-2细胞凋亡，并可以增强Cl-caspase-3，Cl-caspase-9和Cl-PARP的表达。此外，蛋白质印迹分析表明，用化合物A1处理HepG-2细胞后，p53蛋白的表达增加，Bax / Bcl-2的比例逐渐增加。然后将细胞质的Bax转运到线粒体，导致Cyt c蛋白释放。因此，结果表明化合物A1通过线粒体途径诱导细胞凋亡，可用于开发新的抗增殖剂。

  DOI：

  10.1016/j.bioorg.2020.104078

文献信息

• Semisynthetic pleuromutilin antimicrobials with therapeutic potential against methicillin-resistant Staphylococcus aureus by targeting 50S ribosomal subunit
  作者：Xiao Wang、Rui Wang、Zhao-Sheng Zhang、Guang-Yu Zhang、Zhen Jin、Rong Shen、Dan Du、You-Zhi Tang

  DOI：10.1016/j.ejmech.2022.114341

  日期：2022.7

  successfully localized inside the binding pocket of 50S ribosomal subunit (ΔGb = −9.40 kcal/mol). Meanwhile, most of these compounds had no significant inhibitory effect on RAW 264.7 cells and 16HBE cells at the concentration of 8 μg/mL. The obtained outcomes showed that compound 30a could be utilized as an encouraging perspective in the development of a new therapeutic candidate for bacterial infection.

  设计、合成了一系列具有取代的1,2,4-三唑的截短侧耳素类似物，并评估了它们的体外和体内抗菌活性。最初，通过肉汤稀释法测试了合成的衍生物对五株金黄色葡萄球菌（MRSA ATCC 43300、金黄色葡萄球菌ATCC 29213、临床分离的金黄色葡萄球菌AD3、金黄色葡萄球菌144 和金黄色葡萄球菌SA17）的 MIC。 。化合物30a 、 31b和32a是体外针对MRSA最有效的抗菌剂(MIC=0.0625μg/mL)。时间杀灭曲线结果表明，化合物30a和32a可以在体外快速减少MRSA的量（减少-7.70 log 10 CFU/mL和-7.10 log 10 CFU/mL）。在进一步评估化合物30a针对MRSA的体内抗菌活性的实验中，化合物30a （-1.71 log10 CFU/g）可有效减少大腿感染小鼠的MRSA载量。在小鼠全身模型中，化合物30a （存活率为50%）显示出优于泰妙菌素
• 3-Mercapto-1,2,4-triazoles and N-acylated thiosemicarbazides as metallo-β-lactamase inhibitors
  作者：Faridoon、Waleed M. Hussein、Peter Vella、Nazar Ul Islam、David L. Ollis、Gerhard Schenk、Ross P. McGeary

  DOI：10.1016/j.bmcl.2011.10.116

  日期：2012.1

  The production of beta-lactamases is an effective strategy by which pathogenic bacteria can develop resistance against beta-lactam antibiotics. While inhibitors of serine-beta-lactamases are widely used in combination therapy with b-lactam antibiotics, there are no clinically available inhibitors of metallo-beta-lactamases (MBLs), and so there is a need for the development of such inhibitors. This work describes the optimisation of a lead inhibitor previously identified by fragment screening of a compound library. We also report that thiosemicarbazide intermediates in the syntheses of these compounds are also moderately potent inhibitors of the IMP-1 MBL from Pseudomonas aeruginosa. The interactions of these inhibitors with the active site of IMP-1 were examined using in silico methods. (C) 2011 Elsevier Ltd. All rights reserved.
• Synthesis of some N-(5-aryl/aryloxymethyl-1,3,4-thiadiazol-2-yl)glyoxylamide thiosemicarbazones as potential antiviral and antifungal agents.
  作者：S. GIRI、NIZAMUDDIN、U. C. SRIVASTAVA

  DOI：10.1271/bbb1961.47.103

  日期：——
• Giri,S.; Singh,H., Journal of the Indian Chemical Society, 1964, vol. 41, p. 295 - 298
  作者：Giri,S.、Singh,H.

  DOI：——

  日期：——
• Tozkoparan, Birsen; Kilcigil, Guelguen Ayhan; Ertan, Rahmiye, Arzneimittel-Forschung/Drug Research, 1999, vol. 49, # 12, p. 1006 - 1011
  作者：Tozkoparan, Birsen、Kilcigil, Guelguen Ayhan、Ertan, Rahmiye、Ertan, Mevluet、Kelicen, Pelin、Demirdamar, Ruemeysa

  DOI：——

  日期：——